Icaden V

Quick links to important sections

Icaden V

Treatment option: Empeines

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Icaden V

Quick Facts

Property Description
Active ingredient Isoconazole nitrate (INN: Isoconazole)
Form Cream, Ointment, Vaginal Suppository
Pharmacological class Azole Antifungal Agent; Imidazole Derivative
Common use Anti-infective agent for localized fungal pathogens
Origin Synthetic small molecule drug

What Type of Medicine is Icaden V?

Icaden V is a synthetic pharmaceutical preparation centered on the active component, Isoconazole nitrate, which is categorized as an Azole Antifungal Agent. This places the medicine within the broader chemical group of Imidazole Derivatives, a structural family clinically recognized for high effectiveness in fighting common fungal organisms. Isoconazole is classified for both dermatological and gynecological use.

Its identity is rooted in its entirely synthetic nature and its focused activity as a broad-spectrum antimycotic. Isoconazole demonstrates high effectiveness against the specific pathogens typically involved in fungal skin infections, affirming its design for concentrated local treatment.

Composition and Physical Form

The medicine is typically a single-agent product, containing Isoconazole nitrate as its sole active pharmaceutical ingredient. It is designed exclusively for Topical or Vaginal route of administration, which is a key differentiating factor from oral antifungal medications intended for systemic use.

Icaden V is provided in various topical formulations, including a cream or ointment for external skin application (cutaneous route), and sometimes vaginal suppositories for mucosal use. The final composition delivers the active ingredient via an inert base, such as an emulsion cream base, ensuring the high concentration of the active ingredient is applied directly to the site of infection while limiting systemic exposure.

General Purpose as a Broad-Spectrum Antimycotic

The primary purpose of Icaden V is to resolve localized infections caused by sensitive fungi, functioning as a highly effective anti-infective agent. The therapeutic benefit stems from the drug's ability to compromise the structural integrity of the fungal cell wall. This fungicidal (cell-killing) and fungistatic (growth-stopping) activity is designed to address the root cause of the infection.

Furthermore, Isoconazole demonstrates an ancillary action against certain Gram-positive bacteria. This action suggests the medicine may provide a therapeutic advantage in localized infections where bacterial presence is suspected alongside the fungal pathogen.

What side effects are possible with Icaden V?

Possible side effects and safety information

The safety profile for Icaden V (Isoconazole nitrate) is primarily characterized by local reactions due to the medicine's topical and vaginal route of administration. These local effects are classified in regulatory documents as the most commonly reported adverse reactions.

Adverse Reactions by System-Organ Class

The most frequently observed adverse reactions are categorized under Skin and Subcutaneous Tissue Disorders and Reproductive System and Breast Disorders for vaginal use. These include local irritation, a sensation of heat, redness (erythema), itching (pruritus), swelling sensation, and vaginal pain. Due to the nature of the product, the label notes that contact with the face must be carefully managed to avoid contact with the eyes, which can cause serious eye irritation.

Serious and Rare Reactions

Official regulatory documents classify signs of a rare systemic allergic reaction as the most clinically significant adverse events. These signs may include generalized rash, severe itching, swelling, dizziness, and trouble breathing, which are associated with the Immune System Disorders class. The medicine is contraindicated in individuals with known hypersensitivity to Isoconazole nitrate or any of the inactive ingredients.

Safety Considerations and Restrictions

The potential for systemic exposure with topical use is low. However, regulatory information notes that this risk increases if the product is applied extensively to large surface areas of the body or for prolonged periods. Use during the first trimester of pregnancy is generally restricted or requires close physician review, as systemic exposure cannot be entirely ruled out. The medicine is also contraindicated for use on skin affected by specific non-infectious conditions such as viral diseases or syphilitic processes.

Overdose and Emergency Response

Icaden V Overdose and when to seek help

Official regulatory documentation for Icaden V (Isoconazole nitrate) outlines the drug's overdose profile based on its pharmacological properties and route of administration.

Overdose Risk and Acute Toxicity

Isoconazole is an antifungal medication primarily intended for topical or vaginal use. Regulatory authorities have determined that due to the very low systemic absorption of the active ingredient through the skin or mucous membranes, there is no expected risk of acute intoxication.

This finding applies even in cases of accidental topical overdose, such as application over a large skin area, or following unintentional oral ingestion. Consequently, regulatory labels do not document specific systemic signs, symptoms, or life-threatening manifestations resulting from an acute overdose.

Management and Seeking Urgent Help

Overdose Data Field Official Regulatory Data Summary
Documented Manifestations None (acute systemic effects are not expected)
Antidote or Specific Treatment None described or required
Emergency Actions Required No specific procedures are mandated

Because the risk of acute systemic poisoning is considered negligible, official prescribing information does not define explicit conditions under which immediate medical help must be sought for an acute overdose event. Management, if deemed necessary, is generally symptomatic and supportive, as detailed in standard medical formularies, but no specific overdose protocol is mandated by drug labeling.

Therapeutic Uses of Icaden V

Icaden V is commonly used in situations involving certain distressing symptoms related to superficial fungal conditions.

The medication is used for managing common conditions characterized by active fungal growth, including tinea pedis (athlete's foot), tinea cruris (jock itch), and vulvovaginal candidiasis. It helps address symptom clusters that include scaling, redness, intense itching (pruritus), and a burning sensation.

“The symptomatic relief offered by this type of localized therapy supports the patient during difficult episodes by easing distress.”

Icaden V is relevant in contexts marked by increased discomfort or tension, often applied in settings where additional management of discomfort is required. This supportive relief contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Quick Fact: Symptom Management Focus
Symptom Axes Itching, Burning, Redness
Condition Context Episodic, Inflammatory States
Core Benefit Supports Symptom Management

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Icaden V (Isoconazole Nitrate)

This section details the official eligibility and non-eligibility status for Icaden V (Isoconazole Nitrate) according to government regulatory documents.


Contraindications and Restrictions

Status Population/Condition
Must Not Use (Contraindicated) Individuals with known hypersensitivity to the active substance (isoconazole nitrate) or to any of the specific excipients in the product formulation.
Use with Restriction (Conditional) Patients concurrently using latex barrier methods (such as condoms or diaphragms). Certain excipients may damage the latex, impairing the method's effectiveness.

Special Population Status

Pregnancy and Lactation:

  • Pregnancy: While available data do not indicate a teratogenic risk in humans, use must be carefully assessed. Extensive or prolonged application is generally not recommended during pregnancy.
  • Lactation: Although only very small amounts are likely to pass into breast milk, nursing mothers should not apply the product to the breasts to avoid accidental ingestion by the infant.

Age Groups:

  • Use in children and adolescents is not universally restricted, but safety and dosage data may be limited or not established in this population, requiring medical guidance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Profile

The interaction profile of Icaden V (Isoconazole nitrate) is fundamentally defined by its route of administration as a topical or vaginal medicine. Authoritative regulatory documents note that the systemic absorption of the active ingredient following application is low, which dictates the probability of systemic drug interactions.

Interaction Type Regulatory Status (Topical/Vaginal Use)
Documented Systemic Interactions None. Regulatory documentation explicitly states that no interactions have been documented to date.
Formal Contraindications None. No medicinal products are formally listed as contraindicated due to systemic interaction risk.
Metabolic Interactions (CYP) Minimal Risk. The quantity of the drug absorbed is too small to cause clinically relevant alteration of hepatic drug-metabolizing enzymes.

Interaction Constraints

Due to the minimal systemic exposure, the official prescribing information includes no specific warnings regarding co-administration with other systemic medicines. No mandatory requirements for the timing or separation of doses are specified. Furthermore, the official labeling contains no documented restrictions concerning the co-use of the medicine with food, alcohol, or common herbal products, reflecting the lack of systemic pharmacokinetic activity.

Mechanism of Action

Inhibition of Fungal Ergosterol Biosynthesis

Isoconazole's primary mechanism involves the inhibition of the critical fungal enzyme lanosterol 14alpha-demethylase. This blocks the Ergosterol Biosynthesis Pathway, causing the depletion of vital ergosterol and the accumulation of toxic 14alpha-methyl sterols within the pathogen. This molecular action fundamentally compromises the structural integrity and function of the fungal cell membrane, resulting in fungicidal (cell-killing) and fungistatic (growth-stopping) physiological consequences.


Dual Mechanism Affecting Pathogen Viability

The drug exhibits a dual mechanism affecting pathogen viability. In addition to destroying the fungal cell membrane, Isoconazole exerts a distinct effect against certain co-existing Gram-positive bacteria by promoting oxidative stress through the induction of Reactive Oxygen Species (ROS) within the bacterial cells. This secondary mechanism results in an antibacterial physiological effect, which reflects activity against two distinct classes of pathogens.


Mechanism Profile: Rapid Onset and Local Reservoir

The onset of the drug's activity is driven by the rapid molecular effect of inhibiting energy processes, indicated by a swift reduction in intracellular ATP. Furthermore, the localized application creates a sustained drug reservoir within the tissue. This concentration-dependent mechanism maintains continuous and prolonged exposure of the pathogen to fungicidal levels, resulting in a persistent local anti-pathogen physiological consequence.

Dosage and Administration Information

Icaden V, which contains the active component Isoconazole nitrate, is approved for use through localized administration via the topical (skin) and vaginal routes. This medicine is not an oral agent and must not be taken by mouth.


Instruction Detail
Route of administration Topical (Cutaneous) and Vaginal (mucosal).
Dosing schedule Vaginal: A single 600 mg dose used once weekly; or a 100 mg unit administered once daily. Topical: Applied once daily to the affected skin areas at a 1% concentration.
Course Duration Vaginal: A single application for the 600 mg regimen, or a course of seven consecutive days for the daily cream regimen. Topical: Treatment typically lasts 2 to 3 weeks, extending for at least two more weeks after clinical resolution to help prevent recurrence.
Special Procedural Conditions Vaginal applications must be inserted deeply, generally at bedtime. Treatment should not be carried out during menstruation. For skin use, the application site must be thoroughly dried.
Missed-dose rules If a dose is missed, it should be used as soon as possible; two doses must not be administered together to compensate.

The usage protocol is structured by localized delivery and finite treatment courses, requiring compliance with the specified administration route, numerical dosage, and predetermined duration to satisfy the established protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Icaden V

Evidence Base for Vulvovaginal Candidiasis (VVC)

Studies examining Icaden V for vaginal fungal infections (VVC) have included clinical studies and comparative trials. These studies were evaluated in women of reproductive age, used in observational settings evaluating daily-life functioning for a condition characterized by fluctuating or episodic manifestations. The research was studied for both monotherapy and comparison against other established azole antifungals.

The research monitored outcomes related to physical discomfort, such as the outcomes related to the evolution of patient-reported symptoms like itching, burning, and discharge. They also consistently assessed Mycological Endpoints, which involve laboratory confirmation that the presence or absence of the fungal organism was sought to be cleared. Findings describe patterns observed in the studies where reported rates of fungal clearance and symptom evolution were observed alongside those reported for other topical azole treatments used for uncomplicated VVC.


Evidence Base for Superficial Dermatophyte Infections

Research exploring Icaden V for common fungal skin conditions, such as tinea infections, was evaluated in short-term controlled clinical trials and multicenter retrospective studies. These studies monitored responses over defined time intervals, research examining temporary physiological imbalance during periods of increased symptom activity. The populations studied were typically adult patients with confirmed dermatomycoses, including those presenting with cycles of stability and flare-ups related to inflammatory or irritative states.

Research examined two main outcomes: Clinical Success and Mycological Endpoints. Clinical Success measured outcomes linked to inflammatory or irritative states by using grading scales to assess changes in physical signs like scaling, erythema, and patient-reported outcomes describing perceived discomfort. Mycological Endpoints were measured to assess whether the presence or absence of the causative fungus was assessed according to laboratory tests. Findings describe patterns observed in the studies where measurable endpoints, such as mycological clearance, were observed in studies where monotherapy was evaluated.


The Study Landscape: Key Evidence Gaps

Evidence quality varies across studies, and several research limitation frames exist in the current landscape for Icaden V. One key area of uncertainty is the scarcity of recent, large-scale, placebo-controlled RCTs focusing purely on Isoconazole nitrate monotherapy for its indications. Comparative evidence is lacking in the form of robust head-to-head trials against all topical azoles. The evidence highlights what is known, but findings describe group patterns, not personal outcomes; clearer insight into long-term effects remains an area for further study.

Frequently Asked Questions (FAQ)

Common questions about Icaden V (FAQ)

Q: Does Icaden V come in different strengths?

A: Official product information indicates that Icaden V is available in different formulations and concentrations. These variations include different unit dosages for vaginal use, such as a single high dose or a lower daily dose, as well as a specific percentage cream concentration for topical application on the skin.

Q: How quickly should I start feeling better after using Icaden V?

A: Studies and official information on this class of medicine suggest that symptomatic relief for issues like itching and burning can begin within a few days after starting treatment. Full clinical improvement is generally considered to require completing the entire prescribed course.

Q: Does using Icaden V affect birth control pills or other hormonal contraception?

A: Regulatory documents state that no systemic interactions have been documented for this medicine. This is because only a very small amount of the active ingredient is absorbed into the bloodstream. This finding, based on the low level of systemic absorption, means the product is not expected to interfere with the effectiveness of oral hormonal contraceptives.

Q: What happens if I accidentally swallow some Icaden V?

A: The product is strictly for localized application (topical or vaginal), and oral ingestion is not intended. Official safety information notes that if a sufficient amount is absorbed accidentally, it may rarely result in temporary systemic reactions, such as a headache or nausea.

Q: How is the mechanism of action of Icaden V described in simple terms?

A: The medicine works primarily by damaging the cell structure of the fungi, which prevents their growth and causes them to die. In addition to this main fungicidal effect, it is also described in official documents as having a supplementary effect against certain Gram-positive bacteria.

Q: Can men use Icaden V for related skin conditions? (Descriptive only)

A: Official documentation specifies that the topical cream formulation is indicated for the treatment of fungal skin infections (dermatomycoses). This approved use for skin conditions applies generally to adult patients regardless of their sex.

Q: Does Icaden V cause vaginal discharge or change the odor?

A: The drug’s most common side effects are local reactions, such as irritation and burning, and official safety lists do not typically include vaginal odor change as an adverse event. While studies monitor discharge as an outcome related to the underlying infection, it is not listed as a side effect caused by the medicine itself.

Q: What kinds of personal care products should I avoid while using Icaden V?

A: Official warnings specifically advise against using latex barrier contraceptives concurrently, such as condoms or diaphragms. This is because certain non-active ingredients (excipients) are known to damage the latex material, which is a contraindication for concurrent use.

Q: Why does the packaging for Icaden V sometimes mention a specific type of fungus?

A: Regulatory documents require the medicine to specify its approved therapeutic use. Therefore, the packaging will often mention specific species of fungi, such as Candida or Tinea, to confirm that the product is active against the pathogens that define its indication.

Q: Is it necessary to complete the full course of Icaden V even if symptoms disappear early?

A: Official guidance describes the duration of use required to address the condition. For skin infections, official instructions recommend continuing the application for at least two weeks after the visible symptoms have disappeared. This duration of use is described in official documents as necessary for addressing the condition and to help prevent its recurrence.

Q: Is it true that Icaden V can cause headache or stomach upset?

A: Official safety documents list the possibility of experiencing systemic adverse events such as a headache and nausea. However, these are reported to be rare because the medicine’s localized route of administration means very little is absorbed into the main circulatory system.

Q: What is the typical timeframe before common side effects of Icaden V go away?

A: The most common local side effects, which include temporary symptoms like itching or a burning sensation, are generally described in regulatory summaries as being transient. These local reactions are expected to stop soon after the full treatment course is completed.

Q: Does Icaden V cause long-term side effects?

A: Regulatory warnings caution that using the product too extensively or for longer than recommended can increase the risk of systemic absorption. In rare cases associated with such use, effects like localized skin thinning or weakening have been noted in official documents.

Q: What is the function of the applicator device that sometimes comes with Icaden V?

A: The applicator is included with the vaginal formulations to ensure proper use. Its function is to help the patient administer the product correctly and ensure that it is inserted deeply as required by the official instructions for concentrated local delivery.

Q: What are the known components of Icaden V's non-active ingredients (excipients)?

A: Official product composition documents, such as the Summary of Product Characteristics (SmPC), include a complete listing of all the non-active ingredients. These components, known as excipients, are necessary for the specific formulation (cream, suppository) but do not contribute to the main therapeutic effect.

How should Icaden V be stored and disposed of?

How to Store and Dispose of Icaden V

The storage and disposal of Icaden V (Isoconazole Nitrate) are governed by regulatory requirements to ensure product integrity and public safety.

Requirement Type Official Instructions
Temperature Restriction Store at a temperature not exceeding 30 C to maintain stability.
Container Requirement Keep the product in its original container to protect it from the environment.
Child Safety The medicine must be kept out of the sight and reach of children at all times.
Disposal Instructions Any unused or expired product must be disposed of in accordance with local requirements for pharmaceutical waste.

Following these mandatory labeled conditions is required to preserve the quality of the medicine until its use and ensure responsible handling of medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Icaden V found in:

A-Z Index: